Azathioprine in Recurrent Implantation Failure

NCT ID: NCT03498703

Last Updated: 2019-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-25

Study Completion Date

2019-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Azathioprine increase pregnancy rate in patients with recurrent implantation failure

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Implantation Failure In Vitro Fertilization Intracytoplsmic Sperm Injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azathioprine

Group Type EXPERIMENTAL

Azathioprine Pill

Intervention Type DRUG

Azathioprine increase pregnancy rate in cases with recurrent implantaion failure

Control

Group Type PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type DRUG

Placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azathioprine Pill

Azathioprine increase pregnancy rate in cases with recurrent implantaion failure

Intervention Type DRUG

Placebo Oral Tablet

Placebo tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age: 20-39
* previous 3 or more failed ivf

Exclusion Criteria

* intrauterine anomalies
* chronic systemic illness
* chronic pelvic conditions
* sensitivety to azathioprine
Minimum Eligible Age

20 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Capital Birth Center

UNKNOWN

Sponsor Role collaborator

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Reda

Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed H Salama

Role: STUDY_DIRECTOR

Capital Birth Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University, Maternity Hospital

Cairo, , Egypt

Site Status

Capital Birth Center

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FW000372

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intralipid for Repeated Implantation Failure
NCT01540591 COMPLETED PHASE2/PHASE3